The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

1. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ (2013) Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 56: 973–984. doi: 10.1007/s00125-013-2856-6 23494446

2. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837–853. 9742976

3. Klarenbach S, Cameron C, Singh S, Ur E (2011) Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ 183: E1213–E1220. doi: 10.1503/cmaj.110178 21969406

4. Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (Suppl): 789–830. 4926376

5. Genuth S (2015) Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on! Diabetes Care 38: 170–175. doi: 10.2337/dc14-0565 25538314

6. Abrahamson MJ (2015) Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 38: 166–169. doi: 10.2337/dc14-1945 25538313

7. Nissen SE (2012) Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med 157: 671–672. doi: 10.7326/0003-4819-157-9-201211060-00016 23128866

8. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, et al. (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK General Practice Research Database. BMJ 339: b4731. doi: 10.1136/bmj.b4731 19959591

9. Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter M, et al. (2015) Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia 58: 505–518. doi: 10.1007/s00125-014-3473-8 25512005

10. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC (2014) Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care 37: 985–992. doi: 10.2337/dc13-2097 24198301

11. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, et al. (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232–242. doi: 10.1056/NEJMoa1501352 26052984

12. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317–1326. doi: 10.1056/NEJMoa1307684 23992601

13. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, et al. (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327–1335. doi: 10.1056/NEJMoa1305889 23992602

14. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, et al. (2014) Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 311: 2288–2296. doi: 10.1001/jama.2014.4312 24915260

15. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, et al. (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32: 1900–1908. doi: 10.1093/eurheartj/ehr077 21471135

16. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, et al. (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157: 601–610. doi: 10.7326/0003-4819-157-9-201211060-00003 23128859

17. Sedgwick P (2013) Prospective cohort studies: advantages and disadvantages. BMJ: 347: f6726.

18. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30: 389–394. 17259518

19. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, et al. (2013) Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 4: CD009008. doi: 10.1002/14651858.CD009008.pub2 23633364

20. Monami M, Genovese S, Mannucci E (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15: 938–953. doi: 10.1111/dom.12116 23594109

21. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN (2013) Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 30: 1160–1171. doi: 10.1111/dme.12232 23663156

22. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31: 1672–1678. doi: 10.2337/dc08-0167 18458139

23. Bolland MJ, Grey A, Gamble GD, Reid IR (2014) The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2: 364–365.

24. Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61: 64–75. 18083463

25. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, et al. (2011) User manual for Trial Sequential Analysis (TSA). Copenhagen: Copenhagen Trial Unit, Centre for Clinical Intervention Research. 115 p.

26. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. London: Cochrane Collaboration.

27. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535. doi: 10.1136/bmj.b2535 19622551

28. Bu S, Xing XY, Wang N, Zhao WH, Yang WY (2004) [Evaluation of the efficacy and safety of once daily injection of glargine combined with glipizide GITS in the treatment of type 2 diabetes mellitus]. Chin J Evid Based Med 4: 464–467.

29. Li MK, Liu Q, Yu ZZ, Cui SM, Shi P, et al. (1999) [Observation of the effect of combination of glipizide and insulin for type2 diabetic patients with secondary failure to oral sulfonylureas]. J Clin Int Med 15: 38.

30. Onuchin SG, Elsukova OS, Solov’ev OV, Onuchina EL (2010) [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. Ter Arkh 82: 34–41.

31. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343: d5928. doi: 10.1136/bmj.d5928 22008217

32. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, et al. (2008) Incorporating considerations of resources use into grading recommendations. BMJ 336: 1170–1173. doi: 10.1136/bmj.39504.506319.80 18497416

33. Phung OJ, Scholle JM, Talwar M, Coleman CI (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303: 1410–1418. doi: 10.1001/jama.2010.405 20388897

34. Gross JL, Kramer CK, Leitao CB, Hawkins N, Viana LV, et al. (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 154: 672–679. doi: 10.7326/0003-4819-154-10-201105170-00007 21576535

35. Diamond GA, Bax L, Kaul S (2007) Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147: 578–581. 17679700

36. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26: 53–77. 16596572

37. Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23: 1351–1375. 15116347

38. Rucker G, Schwarzer G, Carpenter JR, Schumacher M (2008) Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 8: 79. doi: 10.1186/1471-2288-8-79 19036172

39. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, et al. (2006) Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 67: 235–240. 16864814

40. Ahren B, Johnson SL, Stewart M, Cirkel DT, Yang F, et al. (2014) HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37: 2141–2148. doi: 10.2337/dc14-0024 24898304

41. Alvarsson M, Berntorp K, Fernqvist-Forbes E, Lager I, Steen L, et al. (2010) Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Rev Diabet Stud 7: 225–232. doi: 10.1900/RDS.2010.7.225 21409314

42. Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, et al. (2013) Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 61: 579–587. doi: 10.1053/j.ajkd.2012.11.043 23352379

43. Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, et al. (2013) Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 36: 1067–1073. doi: 10.2337/dc12-1365 23248197

44. Birkeland KI, Rishaug U, Hanssen KF, Vaaler S (1996) NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia 39: 1629–1633. 8960854

45. Campbell IW, Menzis DG, Chalmers J, McBain AM, Brown IRF (1994) One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 20: 394–400. 7843470

46. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941–950. doi: 10.1016/S0140-6736(13)60683-2 23850055

47. Clauson P, Karlander S, Steen L, Efendic S (1996) Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabet Med 13: 471–477. 8737030

48. Del Prato S, Camisasca R, Wilson C, Fleck P (2014) Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab 16: 1239–1246. doi: 10.1111/dom.12377 25132212

49. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, et al. (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11: 157–166. doi: 10.1111/j.1463-1326.2008.00994.x 19125777

50. Filozof C, Gautier JF (2010) A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 27: 318–326. doi: 10.1111/j.1464-5491.2010.02938.x 20536495

51. Foley JE, Sreenan S (2009) Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 41: 905–909. doi: 10.1055/s-0029-1234042 19705345

52. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, et al. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 379: 2270–2278. doi: 10.1016/S0140-6736(12)60479-6 22683137

53. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, et al. (2012) 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380: 475–483. doi: 10.1016/S0140-6736(12)60691-6 22748821

54. Garber A, Henry RR, Ratner R, Hale P, Chang CT, et al. (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabet Obes Metab 13: 348–356.

55. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA (2005) PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28: 2093–2099. 16123472

56. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, et al. (2010) Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 121: 1176–1187. doi: 10.1161/CIRCULATIONAHA.109.881003 20194881

57. Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB (2010) Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 16: 111–117. doi: 10.1111/j.1751-7133.2010.00154.x 20557330

58. Göke B, Gallwitz B, Eriksson JG, Hellqvist A, Gause-Nilsson I (2013) Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 67: 307–316. 23638466

59. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M (2008) Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 116: 6–13. 18095238

60. Hanefeld M, Patwardhan R, Jones NP (2007) A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 17: 13–23. 17174222

61. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357: 28–38. 17551159

62. Hong J, Zhang Y, Lai S, Lv A, Su Q, et al. (2013) Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36: 1304–1311. doi: 10.2337/dc12-0719 23230096

63. Jain R, Osei K, Kupfer S, Perez AT, Zhang J, et al. (2006) Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 26: 1388–1395. 16999648

64. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, et al. (1998) Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 83: 1515–1522. 9589648

65. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443. 17145742

66. Kaku K, Rasmussen MF, Nishida T, Seino Y (2011) Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Investig 2: 441–447. doi: 10.1111/j.2040-1124.2011.00128.x 24843528

67. Lundershausen R, Orban S, Pissarek D, Panzram G (1987) [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy—results of a one-year double blind study]. Wien Klin Wochenschr 99: 603–608. 3118579

68. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A (2001) Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 18: 395–401. 11472451

69. Marbury T, Huang WC, Strange P, Lebovitz H (1999) Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 43: 155–166. 10369424

70. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, et al. (2010) Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12: 780–789. doi: 10.1111/j.1463-1326.2010.01233.x 20649630

71. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, et al. (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296: 2572–2581. 17101640

72. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H (2006) Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 22: 385–389. 16506273

73. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34: 2015–2022. doi: 10.2337/dc11-0606 21816980

74. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9: 194–205. 17300595

75. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, et al. (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299: 1561–1573. doi: 10.1001/jama.299.13.1561 18378631

76. Perriello G, Pampanelli S, Brunetti P, di Pietro C, Mariz S (2007) Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. Diab Vasc Dis Res 4: 226–230. 17907113

77. Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, et al. (2009) Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 121: 765–775. doi: 10.1007/s00508-009-1279-3 20047115

78. Petrica L, Vlad A, Petrica M, Jianu CD, Gluhovschi G, et al. (2011) Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Res Clin Pract 94: 22–32. doi: 10.1016/j.diabres.2011.05.032 21726916

79. Quatraro A, Consoli G, Ceriello A, Giugliano D (1986) Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab 12: 315–318. 3545931

80. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, et al. (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2: 691–700. doi: 10.1016/S2213-8587(14)70120-2 24948511

81. Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E (2007) Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab 9: 506–511. 17587393

82. Rosenstock J, Wilson C, Fleck P (2013) Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 15: 906–914. doi: 10.1111/dom.12102 23531118

83. Tolman KG, Freston JW, Kupfer S, Perez A (2009) Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 32: 787–800.

84. Vahatalo M, Ronnemaa T, Viikari J (2007) Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scand J Prim Health Care 25: 147–153. 17846932

85. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170: 477–480. 14970094

86. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559. doi: 10.1056/NEJMoa0802743 18539917

87. US Food and Drug Administration (2008) Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring (Maryland): US Food and Drug Administration.

88. Schernthaner G, Duran-Garcia S, Hanefeld M, Langslet G, Niskanen L, et al. (2015) Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab 17: 630–638. doi: 10.1111/dom.12461 25761977

89. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, et al. (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3: 43–51. doi: 10.1016/S2213-8587(14)70213-X 25466239

90. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385: 2067–2076. doi: 10.1016/S0140-6736(14)62225-X 25765696

91. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2127–2128.

92. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, et al. (2013) Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 10: 289–301. doi: 10.1177/1479164112475102 23449634

93. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, et al. (2013) Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36: 2254–2261. doi: 10.2337/dc13-0356 23690531